Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Oct 13 - Oct 18
In April 2026 the sponsor announced positive topline results from the Phase 3 SYNCHRONIZE-1 obesity trial, but those company-reported data await full peer-reviewed publication and are best treated as preliminary until then
Our nurses will help guide you through the best options during your visit
In in vitro cell experiments using 3T3L1 preadipocytes as a model, treatment with NNMTi significantly reduced preadipocyte differentiation efficiency and markedly downregulated the expression of adipocyte markers (such as PPAR and C/EBP) in a dosedependent manner
an investigational growth-hormone secretagogue that was never FDA-approved
The evidence does not show that supplying extra methionine, inositol and choline by injection to a patient who is not deficient produces weight loss on its own
US$ 20.29
US$ 22.67
US$ 24.91
US$ 22.19
US$ 24.56
